-
1
-
-
84877843704
-
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
-
Abram, M. E., Hluhanich, R. M., Goodman, D. D., Andreatta, K. N., Margot, N. A., Ye, L., et al. (2013). Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 57, 2654-2663. doi: 10.1128/AAC.02568-12.
-
(2013)
Antimicrob. Agents Chemother
, vol.57
, pp. 2654-2663
-
-
Abram, M.E.1
Hluhanich, R.M.2
Goodman, D.D.3
Andreatta, K.N.4
Margot, N.A.5
Ye, L.6
-
2
-
-
84930661275
-
"Primary mutations that confer resistance to raltegravir and elvitegravir are incompatible with the R263K mutation that is associated with low-level resistance to dolutegravir"
-
Melbourne, VIC
-
Anstett, K., Mesplede, T., Quashie, P., and Oliveira, M. W. (2014). "Primary mutations that confer resistance to raltegravir and elvitegravir are incompatible with the R263K mutation that is associated with low-level resistance to dolutegravir, " in Proceedings of the 20th International AIDS Conference, Melbourne, VIC.
-
(2014)
Proceedings of the 20th International AIDS Conference
-
-
Anstett, K.1
Mesplede, T.2
Quashie, P.3
Oliveira, M.W.4
-
3
-
-
77956017859
-
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor
-
Bar-Magen, T., Sloan, R. D., Donahue, D. A., Kuhl, B. D., Zabeida, A., Xu, H., et al. (2010). Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84, 9210-9216. doi: 10.1128/JVI.01164-10.
-
(2010)
J. Virol
, vol.84
, pp. 9210-9216
-
-
Bar-Magen, T.1
Sloan, R.D.2
Donahue, D.A.3
Kuhl, B.D.4
Zabeida, A.5
Xu, H.6
-
4
-
-
84907438682
-
Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency
-
Bastarache, S. M., Mesplede, T., Donahue, D. A., Sloan, R. D., and Wainberg, M. A. (2014). Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency. Viruses 6, 3487-3499. doi: 10.3390/v6093487.
-
(2014)
Viruses
, vol.6
, pp. 3487-3499
-
-
Bastarache, S.M.1
Mesplede, T.2
Donahue, D.A.3
Sloan, R.D.4
Wainberg, M.A.5
-
5
-
-
84882912698
-
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
-
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., et al. (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382, 700-708. doi: 10.1016/S0140-6736(13)61221-0.
-
(2013)
Lancet
, vol.382
, pp. 700-708
-
-
Cahn, P.1
Pozniak, A.L.2
Mingrone, H.3
Shuldyakov, A.4
Brites, C.5
Andrade-Villanueva, J.F.6
-
6
-
-
84886247956
-
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir
-
Canducci, F., Ceresola, E. R., Saita, D., Castagna, A., Gianotti, N., Underwood, M., et al. (2013). In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J. Antimicrob. Chemother. 68, 2525-2532. doi: 10.1093/jac/dkt220.
-
(2013)
J. Antimicrob. Chemother
, vol.68
, pp. 2525-2532
-
-
Canducci, F.1
Ceresola, E.R.2
Saita, D.3
Castagna, A.4
Gianotti, N.5
Underwood, M.6
-
7
-
-
84924166291
-
New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
-
Carganico, A., Dupke, S., Ehret, R., Berg, T., Baumgarten, A., Obermeier, M., et al. (2014). New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J. Int. AIDS Soc. 17(Suppl. 3), 19749. doi: 10.7448/IAS.17.4.19749.
-
(2014)
J. Int. AIDS Soc
, vol.17
, pp. 19749
-
-
Carganico, A.1
Dupke, S.2
Ehret, R.3
Berg, T.4
Baumgarten, A.5
Obermeier, M.6
-
8
-
-
84870060790
-
Emerging patterns and implications of HIV-1 integrase inhibitor resistance
-
Geretti, A. M., Armenia, D., and Ceccherini-Silberstein, F. (2012). Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr. Opin. Infect. Dis. 25, 677-686. doi: 10.1097/QCO.0b013e32835a1de7.
-
(2012)
Curr. Opin. Infect. Dis
, vol.25
, pp. 677-686
-
-
Geretti, A.M.1
Armenia, D.2
Ceccherini-Silberstein, F.3
-
9
-
-
84907358049
-
Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences
-
Grobler, J. A., and Hazuda, D. J. (2014). Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr. Opin. Virol. 8c, 98-103. doi: 10.1016/j.coviro.2014.07.006.
-
(2014)
Curr. Opin. Virol
, vol.8C
, pp. 98-103
-
-
Grobler, J.A.1
Hazuda, D.J.2
-
10
-
-
84922448572
-
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance
-
Hardy, I., Brenner, B., Quashie, P., Thomas, R., Petropoulos, C., Huang, W., et al. (2015). Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J. Antimicrob. Chemother. 70, 405-411. doi: 10.1093/jac/dku387.
-
(2015)
J. Antimicrob. Chemother
, vol.70
, pp. 405-411
-
-
Hardy, I.1
Brenner, B.2
Quashie, P.3
Thomas, R.4
Petropoulos, C.5
Huang, W.6
-
11
-
-
80052847538
-
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)
-
Hare, S., Smith, S. J., Metifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., et al. (2011). Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80, 565-572. doi: 10.1124/mol.111.073189.
-
(2011)
Mol. Pharmacol
, vol.80
, pp. 565-572
-
-
Hare, S.1
Smith, S.J.2
Metifiot, M.3
Jaxa-Chamiec, A.4
Pommier, Y.5
Hughes, S.H.6
-
12
-
-
84921962113
-
Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors
-
Hassounah, S. A., Mesplede, T., Quashie, P. K., Oliveira, M., Sandstrom, P. A., and Wainberg, M. A. (2014). Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J. Virol. 88, 9683-9692. doi: 10.1128/JVI.00947-14.
-
(2014)
J. Virol
, vol.88
, pp. 9683-9692
-
-
Hassounah, S.A.1
Mesplede, T.2
Quashie, P.K.3
Oliveira, M.4
Sandstrom, P.A.5
Wainberg, M.A.6
-
13
-
-
80052847754
-
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
-
Hightower, K. E., Wang, R., Deanda, F., Johns, B. A., Weaver, K., Shen, Y., et al. (2011). Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55, 4552-4559. doi: 10.1128/AAC.00157-11.
-
(2011)
Antimicrob. Agents Chemother
, vol.55
, pp. 4552-4559
-
-
Hightower, K.E.1
Wang, R.2
Deanda, F.3
Johns, B.A.4
Weaver, K.5
Shen, Y.6
-
14
-
-
84930630263
-
Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
-
Hofstra, L. M., Nijhuis, M., Mudrikova, T., Fun, A., Schipper, P., Schneider, M., et al. (2014). Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses. J. Int. AIDS Soc. 17(Suppl. 3), 19755.
-
(2014)
J. Int. AIDS Soc
, vol.17
, pp. 19755
-
-
Hofstra, L.M.1
Nijhuis, M.2
Mudrikova, T.3
Fun, A.4
Schipper, P.5
Schneider, M.6
-
15
-
-
78751697293
-
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor
-
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., et al. (2011). In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55, 813-821. doi: 10.1128/AAC.01209-10.
-
(2011)
Antimicrob. Agents Chemother
, vol.55
, pp. 813-821
-
-
Kobayashi, M.1
Yoshinaga, T.2
Seki, T.3
Wakasa-Morimoto, C.4
Brown, K.W.5
Ferris, R.6
-
16
-
-
84928199537
-
Genetic barrier to resistance for dolutegravir
-
Llibre, J. M., Pulido, F., Garcia, F., Garcia Deltoro, M., Blanco, J. L., and Delgado, R. (2014). Genetic barrier to resistance for dolutegravir. AIDS Rev. 17, 56-64.
-
(2014)
AIDS Rev
, vol.17
, pp. 56-64
-
-
Llibre, J.M.1
Pulido, F.2
Garcia, F.3
Garcia Deltoro, M.4
Blanco, J.L.5
Delgado, R.6
-
17
-
-
84904559099
-
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
-
Malet, I., Gimferrer Arriaga, L., Artese, A., Costa, G., Parrotta, L., Alcaro, S., et al. (2014). New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J. Antimicrob. Chemother. 69, 2118-2122. doi: 10.1093/jac/dku095.
-
(2014)
J. Antimicrob. Chemother
, vol.69
, pp. 2118-2122
-
-
Malet, I.1
Gimferrer Arriaga, L.2
Artese, A.3
Costa, G.4
Parrotta, L.5
Alcaro, S.6
-
18
-
-
84908253044
-
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
-
Mesplede, T., Osman, N., Wares, M., Quashie, P. K., Hassounah, S., Anstett, K., et al. (2014). Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J. Antimicrob. Chemother. 69, 2733-2740. doi: 10.1093/jac/dku199.
-
(2014)
J. Antimicrob. Chemother
, vol.69
, pp. 2733-2740
-
-
Mesplede, T.1
Osman, N.2
Wares, M.3
Quashie, P.K.4
Hassounah, S.5
Anstett, K.6
-
19
-
-
84874039772
-
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
-
Mesplede, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., et al. (2013). Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10, 22. doi: 10.1186/1742-4690-10-22.
-
(2013)
Retrovirology
, vol.10
, pp. 22
-
-
Mesplede, T.1
Quashie, P.K.2
Osman, N.3
Han, Y.4
Singhroy, D.N.5
Lie, Y.6
-
20
-
-
84907429695
-
Is resistance to dolutegravir possible when this drug is used in first-line therapy?
-
Mesplede, T., and Wainberg, M. A. (2014). Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 6, 3377-3385. doi: 10.3390/v6093377.
-
(2014)
Viruses
, vol.6
, pp. 3377-3385
-
-
Mesplede, T.1
Wainberg, M.A.2
-
21
-
-
84897975407
-
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
-
Oliveira, M., Mesplede, T., Quashie, P. K., Moisi, D., and Wainberg, M. A. (2014). Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. Aids 28, 813-819. doi: 10.1097/QAD.0000000000000199.
-
(2014)
Aids
, vol.28
, pp. 813-819
-
-
Oliveira, M.1
Mesplede, T.2
Quashie, P.K.3
Moisi, D.4
Wainberg, M.A.5
-
22
-
-
84905984152
-
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes
-
Pollicita, M., Surdo, M., Di Santo, F., Cortese, M. F., Fabeni, L., Fedele, V., et al. (2014). Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. J. Antimicrob. Chemother. 69, 2412-2419. doi: 10.1093/jac/dku144.
-
(2014)
J. Antimicrob. Chemother
, vol.69
, pp. 2412-2419
-
-
Pollicita, M.1
Surdo, M.2
Di Santo, F.3
Cortese, M.F.4
Fabeni, L.5
Fedele, V.6
-
23
-
-
84863393356
-
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
-
Quashie, P. K., Mesplede, T., Han, Y. S., Oliveira, M., Singhroy, D. N., Fujiwara, T., et al. (2012). Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J. Virol. 86, 2696-2705. doi: 10.1128/JVI.06591-11.
-
(2012)
J. Virol
, vol.86
, pp. 2696-2705
-
-
Quashie, P.K.1
Mesplede, T.2
Han, Y.S.3
Oliveira, M.4
Singhroy, D.N.5
Fujiwara, T.6
-
24
-
-
84887463456
-
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase
-
Quashie, P. K., Mesplede, T., Han, Y. S., Veres, T., Osman, N., Hassounah, S., et al. (2013a). Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob. Agents Chemother. 57, 6223-6235. doi: 10.1128/AAC.01835-13.
-
(2013)
Antimicrob. Agents Chemother
, vol.57
, pp. 6223-6235
-
-
Quashie, P.K.1
Mesplede, T.2
Han, Y.S.3
Veres, T.4
Osman, N.5
Hassounah, S.6
-
25
-
-
84871781846
-
Evolution of HIV integrase resistance mutations
-
Quashie, P. K., Mesplede, T., and Wainberg, M. A. (2013b). Evolution of HIV integrase resistance mutations. Curr. Opin. Infect. Dis. 26, 43-49.
-
(2013)
Curr. Opin. Infect. Dis
, vol.26
, pp. 43-49
-
-
Quashie, P.K.1
Mesplede, T.2
Wainberg, M.A.3
-
26
-
-
84923206490
-
Differential effects of the G118R, H51Y and E138K resistance substitutions in HIV integrase of different subtypes
-
Quashie, P. K., Oliviera, M., Veres, T., Osman, N., Han, Y. S., Hassounah, S., et al. (2014). Differential effects of the G118R, H51Y and E138K resistance substitutions in HIV integrase of different subtypes. J. Virol. 89, 3163-3175. doi: 10.1128/jvi.03353-3314.
-
(2014)
J. Virol
, vol.89
, pp. 3163-3175
-
-
Quashie, P.K.1
Oliviera, M.2
Veres, T.3
Osman, N.4
Han, Y.S.5
Hassounah, S.6
-
27
-
-
84888099693
-
What if HIV were unable to develop resistance against a new therapeutic agent?
-
Wainberg, M. A., Mesplede, T., and Raffi, F. (2013). What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med. 11:249. doi: 10.1186/1741-7015-11-249.
-
(2013)
BMC Med
, vol.11
, pp. 249
-
-
Wainberg, M.A.1
Mesplede, T.2
Raffi, F.3
-
28
-
-
84928902238
-
Simian-tropic HIV as a model to study drug resistance against integrase inhibitors
-
Wares, M., Hassounah, S., Mesplede, T., Sandstrom, P. A., and Wainberg, M. A. (2015). Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. Antimicrob. Agents Chemother. 59, 1942-1949. doi: 10.1128/aac.04829-4814.
-
(2015)
Antimicrob. Agents Chemother
, vol.59
, pp. 1942-1949
-
-
Wares, M.1
Hassounah, S.2
Mesplede, T.3
Sandstrom, P.A.4
Wainberg, M.A.5
-
29
-
-
84892453291
-
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
-
Wares, M., Mesplede, T., Quashie, P. K., Osman, N., Han, Y., and Wainberg, M. A. (2014). The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. doi: 10.1186/1742-4690-11-7.
-
(2014)
Retrovirology
, vol.11
, pp. 7
-
-
Wares, M.1
Mesplede, T.2
Quashie, P.K.3
Osman, N.4
Han, Y.5
Wainberg, M.A.6
-
30
-
-
84904636492
-
Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients
-
White, K. L., Raffi, F., and Miller, M. D. (2014). Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients. Viruses 6, 2858-2879. doi: 10.3390/v6072858.
-
(2014)
Viruses
, vol.6
, pp. 2858-2879
-
-
White, K.L.1
Raffi, F.2
Miller, M.D.3
-
31
-
-
84873025050
-
Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis
-
Xue, W., Jin, X., Ning, L., Wang, M., Liu, H., and Yao, X. (2013). Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J. Chem. Inf. Model. 53, 210-222. doi: 10.1021/ci300541c.
-
(2013)
J. Chem. Inf. Model
, vol.53
, pp. 210-222
-
-
Xue, W.1
Jin, X.2
Ning, L.3
Wang, M.4
Liu, H.5
Yao, X.6
-
32
-
-
84920189964
-
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection
-
Yoshinaga, T., Kobayashi, M., Seki, T., Miki, S., Wakasa-Morimoto, C., Suyama-Kagitani, A., et al. (2015). Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob. Agents Chemother. 59, 397-406. doi: 10.1128/AAC.03909-14.
-
(2015)
Antimicrob. Agents Chemother
, vol.59
, pp. 397-406
-
-
Yoshinaga, T.1
Kobayashi, M.2
Seki, T.3
Miki, S.4
Wakasa-Morimoto, C.5
Suyama-Kagitani, A.6
|